| Alan Hillstead, MD | |
|
1303 N Main St, Cedar City, UT 84721-9746 | |
| (435) 586-2229 | |
| (435) 586-2022 |
| Full Name | Alan Hillstead |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 18 Years |
| Location | 1303 N Main St, Cedar City, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144431958 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | 8692337-1205 (Utah) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wyoming Medical Center | Casper, WY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wyoming Anesthesia, Llc | 8325383953 | 15 |
News Archive
Implants were associated with a decrease in breast cancer risk and an increased lung cancer risk, but these results likely reflect the lifestyles and smoking habits of the women in the study rather than an effect of the implants themselves, the authors conclude.
A new national study done by researchers at Boston University School of Medicine and Boston Medical Center showed large differences in the emergency department and hospital destinations of minority (Black and Hispanic) patients who are transported by emergency medical services when compared with their non-Hispanic white counterparts.
Malignant melanoma is one of the most common and dangerous types of cancer. Researchers at Friedrich-Alexander Universität Erlangen-Nürnberg investigated how and why brown pigmented moles turn into malignant melanoma using innovative robot technology.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).
Flamel Technologies today announced its financial results for the first quarter of 2011.
› Verified 5 days ago
| Entity Name | Wyoming Anesthesia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265908321 PECOS PAC ID: 8325383953 Enrollment ID: O20181228002322 |
News Archive
Implants were associated with a decrease in breast cancer risk and an increased lung cancer risk, but these results likely reflect the lifestyles and smoking habits of the women in the study rather than an effect of the implants themselves, the authors conclude.
A new national study done by researchers at Boston University School of Medicine and Boston Medical Center showed large differences in the emergency department and hospital destinations of minority (Black and Hispanic) patients who are transported by emergency medical services when compared with their non-Hispanic white counterparts.
Malignant melanoma is one of the most common and dangerous types of cancer. Researchers at Friedrich-Alexander Universität Erlangen-Nürnberg investigated how and why brown pigmented moles turn into malignant melanoma using innovative robot technology.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).
Flamel Technologies today announced its financial results for the first quarter of 2011.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alan Hillstead, MD Po Box 912042, Saint George, UT 84791-2042 Ph: (435) 215-0228 | Alan Hillstead, MD 1303 N Main St, Cedar City, UT 84721-9746 Ph: (435) 586-2229 |
News Archive
Implants were associated with a decrease in breast cancer risk and an increased lung cancer risk, but these results likely reflect the lifestyles and smoking habits of the women in the study rather than an effect of the implants themselves, the authors conclude.
A new national study done by researchers at Boston University School of Medicine and Boston Medical Center showed large differences in the emergency department and hospital destinations of minority (Black and Hispanic) patients who are transported by emergency medical services when compared with their non-Hispanic white counterparts.
Malignant melanoma is one of the most common and dangerous types of cancer. Researchers at Friedrich-Alexander Universität Erlangen-Nürnberg investigated how and why brown pigmented moles turn into malignant melanoma using innovative robot technology.
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO).
Flamel Technologies today announced its financial results for the first quarter of 2011.
› Verified 5 days ago